Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.

PURPOSETherapies that produce deep and durable responses in patients with metastatic melanoma are needed. This phase II cohort from the international, single-arm PIVOT-02 study evaluated the CD122-...